| Lung Cancer Treatments and Mutations | Lifetime | 68 | US 41 | 99.76 |
| Cancer Genomics and Diagnostics | Lifetime | 132 | US 85 | 99.69 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 181 | US 105 | 99.53 |
| Colorectal Cancer Treatments and Studies | Lifetime | 113 | US 52 | 99.57 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 202 | US 105 | 99.35 |
| Cancer Research and Treatments | Lifetime | 156 | US 103 | 98.86 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 89 | US 55 | 99.16 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 283 | US 143 | 99.15 |
| CAR-T cell therapy research | Lifetime | 326 | US 203 | 98.99 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 537 | US 254 | 98.55 |
| Melanoma and MAPK Pathways | Lifetime | 107 | US 58 | 98.68 |
| Cancer Treatment and Pharmacology | Lifetime | 443 | US 231 | 98.74 |
| HER2/EGFR in Cancer Research | Lifetime | 403 | US 189 | 98.29 |
| Advanced Breast Cancer Therapies | Lifetime | 228 | US 107 | 98.13 |
| Genetic factors in colorectal cancer | Lifetime | 714 | US 312 | 97.65 |
| Cancer-related Molecular Pathways | Lifetime | 893 | US 448 | 97.16 |
| Cancer therapeutics and mechanisms | Lifetime | 866 | US 429 | 96.01 |
| Liver physiology and pathology | Lifetime | 756 | US 227 | 94.87 |
| Statistical Methods in Clinical Trials | Lifetime | 788 | US 416 | 92.64 |
| Chromatin Remodeling and Cancer | Lifetime | 575 | US 266 | 88.14 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 2 | US 2 | 99.10 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 38 | US 16 | 99.72 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 28 | US 12 | 99.62 |
| Cancer Genomics and Diagnostics | 2021-2025 | 142 | US 73 | 98.90 |
| CAR-T cell therapy research | 2021-2025 | 128 | US 71 | 99.08 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 139 | US 50 | 98.54 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 250 | US 101 | 99.03 |
| Immunotherapy and Immune Responses | 2021-2025 | 136 | US 49 | 97.81 |
| Genetic factors in colorectal cancer | 2021-2025 | 91 | US 38 | 97.26 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 133 | US 69 | 98.27 |
| Cancer Research and Treatments | 2021-2025 | 58 | US 16 | 96.03 |
| Melanoma and MAPK Pathways | 2021-2025 | 52 | US 16 | 96.94 |
| Lung Cancer Research Studies | 2021-2025 | 392 | US 125 | 95.40 |
| Advanced Breast Cancer Therapies | 2021-2025 | 286 | US 105 | 94.91 |
| Neuroblastoma Research and Treatments | 2021-2025 | 295 | US 113 | 92.17 |
| Cancer-related Molecular Pathways | 2021-2025 | 204 | US 90 | 89.93 |
| Cancer Treatment and Pharmacology | 2021-2025 | 663 | US 232 | 88.06 |
| HER2/EGFR in Cancer Research | 2021-2025 | 716 | US 240 | 88.75 |
| Brain Metastases and Treatment | 2021-2025 | 738 | US 324 | 84.99 |
| Protein Kinase Regulation and GTPase Signaling | 2021-2025 | 163 | US 90 | 75.83 |
| Advances in Oncology and Radiotherapy | 2021-2025 | 670 | US 314 | 74.31 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 910 | US 331 | 73.54 |
| Phagocytosis and Immune Regulation | 2021-2025 | 895 | US 225 | 66.30 |
